Back to Browse Journals » OncoTargets and Therapy » Volume 3

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Authors Carmen Diana Schweighofer, Clemens-Martin Wendtner

Published Date March 2010 Volume 2010:3 Pages 53—67

DOI http://dx.doi.org/10.2147/OTT.S3099

Published 30 March 2010

Carmen Diana Schweighofer1, Clemens-Martin Wendtner2

1Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; 2Department of Internal Medicine I, University of Cologne, Cologne, Germany

Abstract: The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
Keywords: CLL, alemtuzumab, Campath, front-line, first-line treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Exceedingly biocompatible and thin-layered reduced graphene oxide nanosheets using an eco-friendly mushroom extract strategy

Muthoosamy K, Bai RG, Abubakar IB, Sudheer SM, Lim HN, Loh HS, Huang NM, Chia CH, Manickam S

International Journal of Nanomedicine 2015, 10:1505-1519

Published Date: 20 February 2015

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets

Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, Lee M, Seo JW, Park ES

Drug Design, Development and Therapy 2015, 9:695-706

Published Date: 30 January 2015

Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release

Manaia EB, Kaminski RCK, Oliveira AG, Corrêa MA, Chiavacci LA

International Journal of Nanomedicine 2015, 10:811-819

Published Date: 22 January 2015

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Byeon HJ, Kim I, Choi JS, Lee ES, Shin BS, Youn YS

International Journal of Nanomedicine 2015, 10:739-748

Published Date: 19 January 2015

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes [Corrigendum]

Perez AP, Casasco A, Schilrreff P, Defain Tesoriero MV, Duempelmann L, Pappalardo JS, Altube MJ, Higa L, Morilla MJ, Petray P, Romero EL

International Journal of Nanomedicine 2015, 10:169-170

Published Date: 29 December 2014

Enhanced transdermal bioavailability of testosterone propionate via surfactant-modified ethosomes

Meng S, Chen Z, Yang L, Zhang W, Liu D, Guo J, Guan Y, Li J

International Journal of Nanomedicine 2013, 8:3051-3060

Published Date: 13 August 2013

Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation

Castagna A, Rinaldi S, Fontani V, Mannu P, Lotti Margotti M

Clinical Interventions in Aging 2011, 6:201-206

Published Date: 25 July 2011